Vardenafil for Erectile Dysfunction
Vardenafil is a highly selective phosphodiesterase type 5 (PDE5) inhibitor approved for treating erectile dysfunction, with demonstrated efficacy across diverse patient populations and a favorable safety profile when used appropriately. 1, 2
Mechanism of Action
Vardenafil works by selectively inhibiting PDE5 in the corpus cavernosum, which blocks the degradation of cyclic guanosine monophosphate (cGMP). This increases cGMP levels, leading to smooth muscle relaxation, enhanced arterial blood flow, and penile erection. Critically, sexual stimulation is required for vardenafil to work—it has no effect without sexual arousal. 3
The drug demonstrates superior selectivity for PDE5 compared to other phosphodiesterases (>15-fold vs PDE6, >130-fold vs PDE1, >1,000-fold vs PDE2-4 and 7-10), which contributes to its efficacy and side effect profile. 3
Dosing
Standard Dosing
- Starting dose: 10 mg taken 25-60 minutes before sexual activity 2, 3
- Available formulations: 2.5 mg, 5 mg, 10 mg, and 20 mg tablets, plus orally disintegrating tablets (ODTs) 1, 3
- Dose titration is essential: Adjust up to 20 mg for improved efficacy or down to 5 mg for better tolerability 2
Special Populations
Elderly patients (≥65 years):
- Start with 5 mg due to 34% higher Cmax and 52% higher AUC compared to younger men 3
Moderate hepatic impairment (Child-Pugh B):
- Start with 5 mg; maximum dose 10 mg (Cmax increased 130%, AUC increased 160%) 3
- Severe hepatic impairment (Child-Pugh C): Not evaluated—use not recommended 3
Renal impairment:
- Mild impairment: No adjustment needed
- Moderate to severe impairment: AUC 20-30% higher; use caution with lower starting doses 3
Patients on CYP3A4 inhibitors:
- Potent inhibitors (ritonavir, indinavir, ketoconazole): Significant dose reduction required
- Moderate inhibitors (erythromycin): Dose adjustment needed 3
Efficacy
Vardenafil demonstrates similar efficacy to other PDE5 inhibitors (sildenafil, tadalafil, avanafil) in the general ED population, with improvements in:
- International Index of Erectile Function (IIEF) scores
- Penetration ability (SEP Q2: 26.36% improvement)
- Maintenance of erection (SEP Q3: 35.18% improvement)
- Up to 86-90% of patients report improved erections 2, 4, 5
Important caveat: Men with diabetes and post-prostatectomy patients have more severe baseline ED and respond less robustly to all PDE5 inhibitors, though vardenafil remains effective. 2
Pharmacokinetics
- Onset of action: 30 minutes to 2 hours (median 60 minutes) 3
- Half-life: 4-5 hours 3
- Bioavailability: ~15% 3
- Food effect: High-fat meals reduce Cmax by 18-50%—take on empty stomach for optimal effect 3
- Metabolism: Primarily hepatic via CYP3A4 3
Contraindications
Absolute Contraindications
Concurrent use with nitrates or nitric oxide donors (nitroglycerin, isosorbide mononitrate/dinitrate, amyl nitrite)
Severe hepatic impairment (Child-Pugh C) 3
Relative Contraindications/Cautions
- Severe renal disease (not adequately studied in dialysis patients) 2
- Concomitant alpha-blocker therapy (significant hypotension risk—requires careful timing and dosing) 6
- Unstable cardiovascular disease
Precautions
Cardiovascular Considerations
- Mild blood pressure effects: Mean maximum decrease of 7 mmHg systolic and 8 mmHg diastolic 3
- Generally well-tolerated in stable cardiovascular disease patients 7, 8
- ED itself is a cardiovascular risk marker—use the diagnosis as an opportunity to assess and address cardiovascular risk 2
Drug Interactions
- CYP3A4 inhibitors significantly increase vardenafil levels—dose adjustment mandatory 3
- Antihypertensive medications: Generally safe but monitor for additive blood pressure lowering 1
- Alpha-blockers require special caution due to hypotension risk 6
QT Interval
Patient Education Critical Points
Common treatment failures result from incorrect use:
- Sexual stimulation is mandatory for effectiveness 2
- Avoid large meals before dosing (reduces absorption) 3
- Multiple trials may be needed to establish efficacy 2
- Timing matters: take 25-60 minutes before anticipated sexual activity 9
Common Side Effects
The most frequently reported adverse events are mild to moderate, transient, and dose-dependent 2:
Most common:
- Headache
- Flushing
- Rhinitis/nasal congestion
- Dyspepsia
- Dizziness
Vardenafil-specific profile:
- Lowest rates of myalgia compared to other PDE5 inhibitors 2
- No reports of abnormal color vision at recommended doses (5-20 mg) 10
- Adverse event rates: 35.3% (5 mg), 45.3% (10 mg), 54.5% (20 mg) vs 21.1% placebo 4
Combination Therapy
Testosterone deficiency + ED:
- Vardenafil combined with testosterone replacement therapy is more effective than vardenafil alone in hypogonadal men 2
- Testosterone alone is NOT effective for ED—PDE5 inhibitor therapy remains necessary 2
Other combinations showing potential benefit:
Clinical Integration
When prescribing vardenafil, follow this algorithm:
- Verify no contraindications (especially nitrate use, severe hepatic impairment)
- Assess patient factors:
- Age ≥65 years → start 5 mg
- Moderate hepatic impairment → start 5 mg, max 10 mg
- Renal impairment → consider lower starting dose
- CYP3A4 inhibitor use → significant dose reduction
- Standard patients: Start 10 mg
- Educate on proper use: Empty stomach, sexual stimulation required, timing 25-60 minutes before activity
- Titrate based on response: Up to 20 mg for efficacy, down to 5 mg for tolerability
- Address cardiovascular risk factors identified through ED diagnosis
The most recent evidence (2025 EAU guidelines) confirms vardenafil's position as a first-line treatment option, with selection based on intercourse frequency and patient preference among the four available PDE5 inhibitors. 1